“…PURPOSE: Despite selection based on human epidermal growth factor receptor 2 (HER2) overexpression, not all HER2-positive patients benefit from trastuzumab therapy. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Pertuzumab is an anti-HER2 antibody, and its binding to tumor cells requires HER2 to be present at the cell membrane. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We hypothesized that miR‐200c contributes to trastuzumab resistance and stemness maintenance in HER2‐overexpressing breast cancer. In this study, we used HER2‐positive SKBR3, HER2‐negative MCF‐7, and their CD44(+)CD24(−) phenotype mammospheres SKBR3‐S and MCF‐7‐S to verify. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Breast cancer is the leading malignancy among Filipino women, with about 23.50% of cases characterized by human epidermal growth factor receptor-2 (HER2) overexpression. Trastuzumab, in addition to standard chemotherapy, is currently recommended as primary treatment for HER2-positive early-stage breast cancer (EBC) in the adjuvant settings, and has been listed in the Philippine National Formulary (PNF) since 2008, but with no current evidence yet on its value for money, to date. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…HER2 gene amplification was not significantly associated with other clinical parameters, including survival. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We present a case of a 46 year-old female with advanced cervical adenocarcinoma and metastatic recurrence in the lungs found to have HER2 mutation who underwent first and second-line HER2-targeted therapy with sustained disease response. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Here we show that, during acquisition of resistance to HER2 inhibition, metabolic rewiring of breast cancer cells favors reliance on exogenous FA uptake over de novo FA synthesis. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Breast cancers can be classified into luminal A, luminal B, HER2 positive and triple-negative subtypes, each with a distinct therapeutic response. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Early identification of cardiac dysfunction by non-invasive imaging in HER2-positive breast cancer patients treated with trastuzumab is challenging. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Uterine serous carcinoma (USC) is an aggressive variant of endometrial cancer overexpressing HER2/neu in about 30% of cases. Trastuzumab, a humanized monoclonal antibody targeting Her2/Neu, in combination with carboplatin/paclitaxel, is considered the preferred regimen for the treatment of advanced or recurrent HER2/Neu+ USC per NCCN guidelines. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: The aim of this study was to evaluate the efficacy and safety of trastuzumab, combined with the FLOT regimen, in the perioperative treatment of resectable HER-2-positive advanced gastric cancer. METHODS: Overall, 45 patients were divided into two groups; 29 patients in the experimental group were treated with trastuzumab combined with FLOT and 16 patients in the control group were treated with FLOT alone. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We report our experience in patients with HER2+ breast cancer (BC) LM treated with intrathecal (IT) trastuzumab +/- IT topotecan. …”
Enlace del recurso
Enlace del recurso

“…Trastuzumab emtansine (T-DM1), an antibody–drug conjugate (ADC) of trastuzumab and cytotoxic agent emtansine (DM1), has been approved for the therapy of metastatic HER2-positive breast cancer after prior treatment of trastuzumab and taxane. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…MATERIALS AND METHODS: This study based on randomized Phase 2 or 3 trials of CDKi plus ET compared with placebo plus ET for women with HR+/HER2−ABC and identify relevant randomized clinical trials (RCTs) published prior to February 2020. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Approximately 20% of breast cancers are HER2-positive. Trastuzumab has improved patient outcomes significantly for these cancers. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Real-world data on HER2 assessment and administration of trastuzumab are lacking. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: Female nude mice were subcutaneously implanted on opposite shoulders with the ER+/HER2− and ER−/HER2+ MCF-7 and JIMT-1 tumor cell lines, respectively. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Trastuzumab (TZMB) is widely used as first line therapy for breast cancer (BC) patients overexpressing human epidermal growth factor receptor 2 (HER2). Despite its clinical benefits, many patients suffer from primary or secondary resistance to this drug within one year. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The development of new HER2-directed therapies has resulted in a significant prolongation of survival for women with metastatic HER2-positive breast cancer. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: HER2 is the target of the therapeutic agents which are used to treat HER2-positive breast cancer. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso